Background of the Invention
1. Field of the Invention
Allergic rhinitis is a chronic medical ailment that afflicts millions of people throughout the industrialized world. Common allergenic substances and conditions are universally prevalent in permutations and combinations that confuse both patients and doctors, that inhibit insight into etiology, that limit doctor-patient communication, that restrict accurate feedback and interpretation of clinical results, and that impair diagnosis and therapy.
2. The Prior Art
A variety of helpful medications now are available, by prescription and over-the-counter, for treating allergic rhinitis. Difficulties have been encountered in systematically prescribing, adapting, monitoring, recording, and adjusting the selection and application of available medications. Allergy avoidance should be the initial focus of any strategy for treating allergic rhinitis, and should be practiced concomitantly with other treatments. Lack of a consistent program for implementing a sound strategy often has resulted in unnecessary use of costly medication and medical services. Prior strategies often have ignored inquiry into environmental factors in a manner that has been insufficiently oriented toward patient self-help and that has caused undue dependence on attention by medical personnel.
Summary of the Invention
The present invention relates to systems and processes for the treatment of allergic rhinitis, and, more particularly, to practical systems and processes for ameliorating the treatment of allergic rhinitis by reducing inherent confusion, encouraging effective patient self-help, improving and expediting medical evaluation and enhancing doctor-patient communication.
Specifically, the system and process of the present invention contemplate combining graphical indicia and medicinal dosages in at least three logically related physical formats, according to at least three medically related clinical steps. The first physical format, in reference to Step 1, presents a plurality of categories of queries regarding allergenic substances and conditions. The second physical format, in reference to Step 2, presents a plurality of categories of actions regarding recommendations for allergy avoidance. The third physical format, in reference to Step 3, presents one or more categories of medicinal dosages in one or more logically related physical regions, which are accompanied by a set of instructions. Preferably, the third physical format includes sequences of modules that are defined in at least one blister-pack array that includes a formed plastic sheet with pockets for receiving the dosages and a rupturable aluminum cover for retaining the dosages in their modules until removed manually.
Each of the categories in Step 1 is designated by a medical identifier that is unique within Step 1. Each of the categories in Step 2 is designated by a medical identifier that is unique within Step 2. Each medical identifier in Step 1 is substantially identical to a corresponding medical identifier in Step 2 and vice versa. The modules of any sequence in Step 3 are in proximity to indicia that designate increments of time. The arrangement is a program of artificial intelligence in which the patient is enabled by medical expertise: to select pertinent allergenic factors which are defined by the queries presented in Step 1; to select pertinent salutary recommendations which are defined by the actions presented in Step 2; and to implement or avoid the medicinal regimen that is provided and defined by the modules and indicia presented in Step 3. The steps together provide interrelated records for current and future evaluation.
The present invention improves patient understanding of allergy causation and treatment strategies, suggests an environmental allergy control plan to the patient, enhances the patient-doctor and care path partnership, improves clinical outcomes, and reduces costs for allergy care.
Brief Description of the Drawings
For a fuller understanding of the nature and objects of the present invention, reference is made to the following specification, which is to be taken in connection with the accompanying drawings, wherein:
FIG. 1 is a flow diagram illustrating the three formats of the system and the three steps of the process of the present invention.
FIGS. 2a and 2b illustrate an example of a printed format for allergy assessment that corresponds to Step 1.
FIGS. 3a, 3b and 3c illustrate an example of a printed format for allergy exposure recommendations that corresponds to Step 2.
FIGS. 4a, 4b, 4c and 4d illustrate an example of a blister pack and printed format for carrying sequences of medicinal dosages, identifying the timing of successive dosages, and providing background medical information.
FIGS. 5a, 5b and 5c illustrate another example of a printed format for allergy exposure recommendations that corresponds to Step 2.
Detailed Description of the Preferred Embodiment
This allergy relief program, in effect, implements a cost-effective model, which standardizes delivery of care for allergic rhinitis. In its preferred embodiment, it includes a plan having three steps. Step 1 provides a record that interactively effects an Allergy Assessment. Step 2 provides a record that effects recommendations for Allergy Exposure Reduction as a function of Step 1. And Step 3 provides at least one sequential array of dosage units, which effect a Medication Regimen that is timed as a function of Steps 1 and 2. After completion, the allergy relief system and process of the present invention provide a permanent record to support current and future treatment.
The allergy relief program of the present invention may be particularly useful within health maintenance organizations (HMO's) and managed care plans, and may be utilized in the context of care criteria for specific patient populations or medical practice patterns. Suggested criteria for inclusion in the care path are stuffy nose, runny nose and sneezing, which may be associated with eye watering and itching, post-nasal drip and sinus fullness. Suggested criteria for exclusion from the care path of the present invention, indicative of infection or other complications, are pain in the sinus areas with fever, ear pain or loss of hearing, loss of sense of smell, severe or persistent sore throat, wheezing, shortness of breath, fever, and rash or joint tenderness. Patients who do not meet the care criteria of the present invention may be directed to their attending physician. Patients with heart disease, high blood pressure, thyroid disease, diabetes, seizure disorders, difficulty in urination due to enlargement of the prostate gland or taking monoamine oxidase (MAO) inhibitors also may require direction by their physicians. After resolution of such complications, patients become eligible to proceed with use of the present invention.
As shown in FIG. 1, the illustrated embodiment physically implements the three steps of the present invention in a combination of graphical indicia and medicinal dosages in at least three logically related physical formats. The first physical format, in reference to Step 1, includes a record containing references to a plurality of categories of allergenic substances and conditions. The second physical format, in reference to Step 2, includes a record containing references to a plurality of categories of recommendations. The third physical format, in reference to Step 3, includes one or more categories of medicinal dosages in one or more logically related physical regions. These dosages, which are accompanied by a set of instructions, are distributed in sequences of modules that are defined in a blister-pack array that includes a formed plastic sheet with pockets for receiving the dosages and a rupturable aluminum cover for retaining the dosages in their modules until removed manually.
As shown in FIGS. 1, 2a and 2b, the first physical format, in reference to Step 1, includes a record that refers to a plurality of categories of interactive base line queries. Each of the categories in Step 1 is designated by a query identifier that is unique within Step 1. Specifically, these query identifiers include POLLENS 20, HOUSE DUST 22, MOLDS 24, PETS 26, MEDICATIONS 28, and AIRBORNE IRRITANTS 30. Each of the categories specified by these query identifiers is followed by a series of queries that are associated with check boxes 32, by which a patient is guided to specify applicable allergenic factors. Each of these queries is followed by a question mark 33.
As shown in FIGS. 1, 3a, 3b and 3c, the second physical format, in reference to Step 2, includes a record that refers to a plurality of categories of responsively recommended actions. Each of the categories in Step 2 is designated by a action identifier that is unique within Step 2. Specifically, these action identifiers include POLLENS 34, HOUSE DUST 36, MOLDS 38, PETS 40, MEDICATIONS 42, and AIRBORNE IRRITANTS 44. Each of the categories specified by these action identifiers is followed by a series of suggested actions that are associated with bullet points 46, by which a patient is guided to take appropriate preventative measures. Each of these actions is followed by an exclamation mark 48.
As shown in FIGS. 1, 4a, 4b and 4c, the third physical format, in reference to Step 3, includes applicable medical information 50, and groups of medicinal dosages in logically related physical regions 52, 54, 55. These dosages are distributed in sequences of modules that are defined in a blister-pack array that includes a formed plastic sheet with pockets for receiving the dosages and a rupturable aluminum cover for retaining the dosages in their modules until removed manually. In the illustrated embodiment, the modules of any sequence in Step 3 are in proximity to indicia 56 that designate increments of time, which establish a time line that is related to the aforementioned query and action identifiers.
In one embodiment, the illustrated allergy relief system contains two blister packs of the type shown in FIGS. 1 and 4b, by which it is adapted for a package, which contains a 14-day medication regimen with pseudoephedrine for day and chlorpheniramine for night. These single entity medications are well characterized and have had long and widespread use. The concept of exploiting the characteristics of separate entities for day and night dosing is disclosed in U.S. Pat. No. 4,295,567. Removing dosages from their modules, after establishing a base line pursuant to Step 1 and following the recommendations of Step 2, inherently optimizes the medicinal regimen of Step 3 and produces a permanent record as a basis for further treatment. Therapeutic benefit is optimized and side effects minimized by this novel dosing regimen.
Another embodiment of the present invention includes an alternative Step 2, which is shown in FIGS. 5a, 5b and 5c. In this embodiment, the second physical format, in reference to Step 2, includes a record that refers to a plurality of categories of responsively recommended actions. Each of the categories in Step 2 is designated by an action identifier that is unique within Step 2. Specifically, these action identifiers include POLLENS 60, HOUSE DUST 62, MOLDS 68, PETS 70, MEDICATIONS 72, and AIRBORNE IRRITANTS 74. Each of the categories specified by these action identifiers is followed by a series of suggested actions that are associated with check boxes 62, by which a patient is guided to take appropriate preventative measures. Each of these actions is followed by an exclamation mark 64.
The medicinal dosages in reference to Step 3 are shown in a blister pack format in the preferred embodiment. However, the present invention contemplates alternative dosage formats, such as liquids, powders, capsules, etc., accompanied by logically related indicia and instructions, which coordinate their use in conjunction with Steps 1 and 2.
Operation
It will be observed that each query identifier in Step 1 is substantially identical to a corresponding action identifier in Step 2 and vice versa. It will be observed also that all of the sections of the sections of the illustrated physical formats as shown in the drawings are of identical size and shape. This identity of format visually aids in comprehending and following the procedures of the present invention. Thus the queries of Step 1 identify relevant allergenic substances and conditions, the recommendations of Step 2 identify relevant needed actions, and the medication regimen of Step 3 provide comprehensive coordinated management of allergic disorders. Removing dosages from their modules pursuant to selected medical identifiers inherently establishes a time line that is related to the aforementioned medical identifiers. The steps together constitute current and future guidance pursuant to a regimen of artificial intelligence that serves as an aid to medical service providers, a self-help guide to patients, and a permanent record for future use by both.